CAREERS AT AMAREX
Feb 17, 2022
Many non-COVID-19 global clinical trials are delayed or terminated early due to the COVID-19 pandemic. The clinical trials carried out by Amarex were not forced to be suspended or terminated during the pandemic. Amarex set up the monitoring plan and audit system remotely and that not only overcomes the difficulty of on-site monitoring but also ensures the quality of clinical trials and the safety and rights of subjects.
Nov 02, 2021
Amarex Taiwan Exhibiting at BIO Asia-Taiwan 2021 | Nov. 4-7 | Taipei, Taiwan
Taipei, Taiwan (November 02, 2021) – We are pleased to announce that Amarex Taiwan, LLC is exhibiting at BIO Asia-Taiwan 2021, held November 4-7 at the Taipei Nangang Exhibition Center in Taiwan.
Sep 16, 2021
Amarex Passes Taiwan FDA GTP Audit: Result is a Resounding No Findings
Taipei, Taiwan (September 16, 2021) – Amarex Taiwan, LLC announces a no findings result of a Taiwan Food and Drug Administration (TFDA) audit of its office last month.
Feb 24, 2021
Amarex Featured in 15-year Anniversary Issue of the NSF International Journal
The just released Issue 48 of NSF International’s Health Science Journal features contributions by Amarex Clinical Research, LLC. This journal is available at https://www.nsf.org/periodicals/health-sciences-journal/issue-48.
Jan 18, 2021
Severe-to-Critical COVID-19 Patient Clinical Trial Reaches Full Enrollment
Our client’s Phase III clinical trial for patients with severe-to-critical COVID-19 symptoms reached full enrollment (390 patients) in mid-December. Data analysis results are expected this quarter. The trial was conducted in the U.S., Canada, and U.K..